Nanoparticle conjugation enhances the immunomodulatory effects of intranasally delivered CpG in house dust mite-allergic mice

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Ballester, Marie ^a   Jeanbart, Laura ^a   De Titta, Alexandre ^a   Nembrini, Chiara ^a   Marsland, Benjamin J ^b   Hubbell, Jeffrey A ^a,c,d   Swartz, Melody A ^a,c  

^a EPFL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF CHICAGO   (United States)

^d ARGONNE NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CPG-OLIGONUCLEOTIDE; CYTOKINE; IMMUNOLOGICAL ADJUVANT; NANOPARTICLE; OLIGODEOXYRIBONUCLEOTIDE;

ANIMAL; BIOSYNTHESIS; DENDRITIC CELL; DRUG EFFECTS; HELPER CELL; HYPERSENSITIVITY; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; MOUSE; PYROGLYPHIDAE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INHALATION; ANIMALS; CYTOKINES; DENDRITIC CELLS; HYPERSENSITIVITY; MICE; NANOPARTICLES; OLIGODEOXYRIBONUCLEOTIDES; PYROGLYPHIDAE; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84942133028     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep14274     Document Type: Article

References (56)

1. Larché, M., Akdis, C. A. & Valenta, R. Immunological mechanisms of allergen-specific immunotherapy. Nat. Rev. Immunol. 6, 761-771 (2006).
2. Holt, P. G., Macaubas, C., Stumbles, P. A. & Sly, P. D. The role of allergy in the development of asthma. Nature 402, B12-17 (1999).
3. Melvin, T.-A. N. & Ramanathan, M. Role of innate immunity in the pathogenesis of allergic rhinitis. Curr. Opin. Otolaryngol. Head Neck Surg. 20, 194-198 (2012).
4. Hayashi, T. & Raz, E. TLR9-based immunotherapy for allergic disease. Am. J. Med. 119, 897.e891-897.e896 (2006).
5. Crameri, R. & Rhyner, C. Novel vaccines and adjuvants for allergen-specific immunotherapy. Curr. Opin. Immunol. 18, 761-768 (2006).
6. Klimek, L., Bachmann, M. F., Senti, G. & Kündig, T. M. Immunotherapy of type-1 allergies with virus-like particles and CpGmotifs. Expert Rev. Clin. Immunol. 10, 1059-1067 (2014).
7. Krieg, A. M. CpG still rocks! Update on an accidental drug. Nucleic Acid Ther. 22, 77-89 (2012).
8. Creticos, P. S. et al. Immunotherapy with a ragweed-Toll-like receptor 9 agonist vaccine for allergic rhinitis. N. Engl. J. Med. 335, 1445 (2006).
9. Reuter, S. et al. TLR3 but not TLR7/8 ligand induces allergic sensitization to inhaled allergen. J. Immunol. 188, 5123-5131 (2012).
10. Fonseca, D. E. & Kline, J. N. Use of CpG oligonucleotides in treatment of asthma and allergic disease. Adv. Drug Deliver. Rev. 61, 256-262 (2009).
11. Wild, J. S. & Sur, S. CpG oligonucleotide modulation of allergic inflammation. Allergy 56, 365-376 (2001).
12. Weiner, G., Liu, H., Wooldridge, J., Dahle, C. & Krieg, A. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. USA. 94, 10833 (1997).
13. Kitagaki, K., Jain, V. V., Businga, T. R., Hussain, I. & Kline, J. N. Immunomodulatory effects of CpG oligodeoxynucleotides on established Th2 responses. Clin. Vaccine Immunol. 9, 1260-1269 (2002).
14. Fransson, M. et al. Expression of Toll-like receptor 9 in nose, peripheral blood and bone marrow during symptomatic allergic rhinitis. Respir. Res. 8, 17 (2007).
15. Jain, V. V. et al. Mucosal immunotherapy with CpG oligodeoxynucleotides reverses a murine model of chronic asthma induced by repeated antigen exposure. Am. J. Physiol. Lung Cell Mol. Physiol. 285, L1137-1146 (2003).
16. Rhee, C.-S. et al. Allergen-independent immunostimulatory sequence oligodeoxynucleotide therapy attenuates experimental allergic rhinitis. Immunology 113, 106-113 (2004).
17. Hayashi, T., Hasegawa, K. & Sasaki, Y. Systemic administration of olygodeoxynucleotides with CpG motifs at priming phase reduces local Th2 response and late allergic rhinitis in Balb/c mice. Inflammation 31, 47-56 (2007).
18. Fonseca, D. M. et al. IFN-γ-mediated efficacy of allergen-free immunotherapy using mycobacterial antigens and CpG-ODN. Immunol. Cell Biol. 89, 777-785 (2011).
19. Campbell, J. D. et al. A limited CpG-containing oligodeoxynucleotide therapy regimen induces sustained suppression of allergic airway inflammation in mice. Thorax 69, 565-573 (2014).
20. Kline, J. N. et al. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J. Immunol. 160, 2555-2559 (1998).
21. Kline, J. N. et al. CpG oligodeoxynucleotides do not requireTH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. J. Allergy Clin. Immunol. 104, 1258-1264 (1999).
22. Takabayashi, K., Libet, L., Chisholm, D., Zubeldia, J. & Horner, A. A. Intranasal immunotherapy is more effective than intradermal immunotherapy for the induction of airway allergen tolerance in Th2-sensitized mice. J. Immunol. 170, 3898-3905 (2003).
23. Suzuki, M., Matsumoto, T., Ohta, N., Min, W. & Murakami, S. Intranasal CpG DNA therapy during allergen exposure in allergic rhinitis. Otolaryngol. Head Neck Surg. 136, 246-251 (2007).
24. Kourtis, I. C. et al. Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice. PLoS One 8, e61646 (2013).
25. de Titta, A. et al. Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc. Natl. Acad. Sci. USA. 110, 19902-19907 (2013).
26. Jeanbart, L. et al. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes. Cancer Immunol. Res. 2, 436-447 (2014).
27. van der Vlies, A. J., O'neil, C. P., Hasegawa, U., Hammond, N. & Hubbell, J. A. Synthesis of pyridyl disulfide-functionalized nanoparticles for conjugating thiol-containing small molecules, peptides, and proteins. Bioconjug. Chem. 21, 653-662 (2010).
28. Ballester, M. et al. Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. Vaccine 29, 6959-6966 (2011).
29. Nembrini, C. et al. Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. Proc. Natl. Acad. Sci. USA. 108, E989-997 (2011).
30. Gómez, J. M. M. et al. A protective allergy vaccine based on CpG-and protamine-containing PLGA microparticles. Pharm. Res. 24, 1927-1935 (2007).
31. Klimek, L. et al. Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clin. Exp. Allergy 41, 1305-1312 (2011).
32. Hammad, H. et al. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nat. Med. 15, 410-416 (2009).
33. Gregory, L. G. & Lloyd, C. M. Orchestrating house dust mite-associated allergy in the lung. Trends Immunol. 32, 402-411 (2011).
34. Trompette, A. et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat. Med. 20, 159-166 (2014).
35. Stano, A. et al. PPS nanoparticles as versatile delivery system to induce systemic and broad mucosal immunity after intranasal administration. Vaccine 29, 804-812 (2011).
36. Li, J., Jiang, H., Wen, W., Zheng, J. & Xu, G. The dendritic cell mannose receptor mediates allergen internalization and maturation involving notch 1 signalling. Clin. Exp. Immunol. 162, 251-261 (2010).
37. Lambrecht, B. N. et al. Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation. J. Clin. Invest. 106, 551-559 (2000).
38. von Gunten, S., Marsland, B. J., von Garnier, C. & Simon, D. Update in clinical allergy and immunology. Allergy 67, 1491-1500 (2012).
39. Nembrini, C. et al. Bacterial-induced protection against allergic inflammation through a multicomponent immunoregulatory mechanism. Thorax 66, 755-763 (2011).
40. Al-Alawi, M., Hassan, T. & Chotirmall, S. H. Transforming growth factor β and severe asthma: A perfect storm. Respir. Med. 108, 1409-1423 (2014).
41. Erle, D. J. & Sheppard, D. Cell biology of disease: The cell biology of asthma. J. Cell Biol. 205, 621-631 (2014).
42. Yazdanbakhsh, M., Kremsner, P. G. & van Ree, R. Allergy, parasites, and the hygiene hypothesis. Science 296, 490-494 (2002).
43. Krieg, A. M. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5, 471-484 (2006).
44. Fattouh, R. et al. Eosinophils are dispensable for allergic remodeling and immunity in a model of house dust mite-induced airway disease. Am. J. Respir. Crit. Care Med. 183, 179-188 (2011).
45. Hammad, H. et al. Inflammatory dendritic cells - not basophils - are necessary and sufficient for induction of Th2 immunity to inhaled house dust mite allergen. J. Exp. Med. 207, 2097-2111 (2010).
46. Kobayashi, H., Horner, A. A., Martin-Orozco, E. & Raz, E. Pre-priming: a novel approach to DNA-based vaccination and immunomodulation. Springer Semin. Immunopathol. 22, 85-96 (2000).
47. Li, A. V. et al. Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination. Sci. Transl. Med. 5, 204ra130 (2013).
48. Joshi, V. B. et al. Development of a poly (lactic-co-glycolic acid) particle vaccine to protect against house dust mite induced allergy. AAPS Journal 16, 975-985 (2014).
49. Volpi, C. et al. High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9-TRIF pathway. Nature Communications 4, 1852-1811 (2013).
50. Klimek, L., Schendzielorz, P., Mueller, P., Saudan, P. & Willers, J. Immunotherapy of allergic rhinitis: New therapeutic opportunities with virus-like particles filled with CpG motifs. American Journal of Rhinology and Allergy 27, 206-212 (2013).
51. Senti, G. et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin. Exp. Allergy 39, 562-570 (2009).
52. Manolova, V. et al. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38, 1404-1413 (2008).
53. Storni, T. et al. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J. Immunol. 172, 1777-1785 (2004).
54. Blank, F. et al. Size-dependent uptake of particles by pulmonary antigen-presenting cell populations and trafficking to regional lymph nodes. Am. J. Respir. Cell Mol. Biol. 49, 67-77 (2013).
55. Blank, F., Stumbles, P. & von Garnier, C. Opportunities and challenges of the pulmonary route for vaccination. Expert Opin. Drug Del. 8, 547-563 (2011).
56. Choi, H. S. et al. Rapid translocation of nanoparticles from the lung airspaces to the body. Nat. Biotechnol. 28, 1300-1303 (2010).